Axon degeneration mechanisms: Commonality amid diversity

Nature Reviews Neuroscience

Volumn 6, Issue 11, 2005, Pages 889-898

  Coleman, Michael ^a  

^a BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' CYCLIC NUCLEOTIDE 3' PHOSPHODIESTERASE; AMYLOID BETA PROTEIN; BEPRIDIL; CALPASTATIN; CHAPERONE; CONTACTIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERYTHROPOIETIN; FLECAINIDE; GUANOSINE TRIPHOSPHATASE; HYDROLASE; PACLITAXEL; PHENYTOIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; SIRTUIN; SUPEROXIDE DISMUTASE; UBIQUITIN;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANOXIA; APOPTOSIS; AUTOIMMUNE DISEASE; BRAIN INJURY; CALCIUM METABOLISM; CALCIUM TRANSPORT; CELL DEATH; CENTRAL NERVOUS SYSTEM DISEASE; ENZYME ACTIVATION; GENE INSERTION; GENE SILENCING; HEREDITARY MOTOR SENSORY NEUROPATHY; HUMAN; IMMUNOCYTOCHEMISTRY; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVE TRANSECTION; NEURITIS; NEUROIMAGING; NEUROPATHY; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHWANN CELL; SPASTIC PARAPLEGIA; SPINAL CORD INJURY; SYNAPSE;

ANIMALS; AXONAL TRANSPORT; AXONS; CENTRAL NERVOUS SYSTEM; HUMANS; NERVE TISSUE PROTEINS; WALLERIAN DEGENERATION;

WALLERIA;

EID: 27644591304     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn1788     Document Type: Review

References (123)

1. Ferri, A., Sanes, J. R., Coleman, M. P., Cunningham, J. M. & Kato, A. C. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr. Biol. 13, 669-673 (2003). Together with references 27 and 28, this paper definitively linked the mechanisms of Wallerian degeneration and 'dying back' neuropathy.
2. Fischer, L. R. et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp. Neurol. 185, 232-240 (2004).
3. Stokin, G. B. et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 307, 1282-1288 (2005). A provocative paper showing that blocking axonal transport worsens symptoms in a mouse model of Alzheimer's disease. Results also suggested that axonal spheroids may be sites of APP processing into Aβ.
4. Li, H., Li, S. H., Yu, Z. X., Shelbourne, P. & Li, X. J. Huntingtin aggregate-associated axonal degeneration is an early pathological event in Huntington's disease mice. J. Neurosci. 21, 8473-8481 (2001).
5. Libby, R. T. et al. Susceptibility to neurodegeneration in glaucoma is modified by Bax gene dosage. PLoS Genet. 1, e4 (2005).
6. Medana, I. M. & Esiri, M. M. Axonal damage: a key predictor of outcome in human CNS diseases. Brain 126, 515-530 (2003). An extensive review of axonal disorders that show accumulation of APP as an indicator of axonal damage and blocked transport.
7. Coleman, M. P. & Perry, V. H. Axon pathology in neurological disease: a neglected therapeutic target. Trends Neurosci. 25, 532-537 (2002).
8. Vaux, D. L. Toward an understanding of the molecular mechanisms of physiological cell death. Proc. Natl Acad. Sci. USA 90, 786-789 (1993).
9. Edinger, A. L. & Thompson, C. B. Death by design: apoptosis, necrosis and autophagy. Curr. Opin. Cell Biol. 16, 663-669 (2004).
10. S gene, and demonstration that the protein product is only detectable in the nucleus in vivo.
11. Feng, G. et al. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 28, 41-51 (2000). Reports the production of multiple transgenic mouse lines that express spectral variants of GFP in specific neuronal subsets, which are now revolutionizing longitudinal and real-time imaging of axon degeneration.
12. Stys, P. K. General mechanisms of axonal damage and its prevention. J. Neurol. Sci. 233, 3-13 (2005).
13. Waller, A. Experiments on the section of glossopharyngeal and hypoglossal nerves of the frog and observations of the alternatives produced thereby in the structure of their primitive fibres. Phil. Trans. R. Soc. Lond. B 140, 423-429 (1850).
14. Lubinska, L. Early course of Wallerian degeneration in myelinated fibres of the rat phrenic nerve. Brain Res. 130, 47-63 (1977).
15. S) nerves. BMC Neurosci. 6, 6 (2005).
16. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science 298, 789-791 (2002).
17. Cavanagh, J. B. The 'dying back' process. A common denominator in many naturally occurring and toxic neuropathies. Arch. Pathol. Lab. Med. 103, 659-664 (1979).
18. Bouldin, T. W. & Cavanagh, J. B. Organophosphorous neuropathy. I. A teased-fiber study of the spatio-temporal spread of axonal degeneration. Am. J. Pathol. 94, 241-252 (1979).
19. Miledi, R. & Slater, C. R. On the degeneration of rat neuromuscular junctions after nerve section. J. Physiol. (Lond.) 207, 507-528 (1970).
20. S mutant and Ube4b/Nmnat transgenic mice. J. Physiol. (Lond.) 543, 739-755 (2002).
21. George, R. & Griffin, J. W. The proximo-distal spread of axonal degeneration in the dorsal columns of the rat. J. Neurocytol. 23, 657-667 (1994).
22. Spencer, P. S. & Schaumburg, H. H. Ultrastructural studies of the dying-back process. III. The evolution of experimental peripheral giant axonal degeneration. J. Neuropathol. Exp. Neurol. 36, 276-299 (1977).
23. S) mouse, which has done much to open up this field.
24. Perry, V. H., Brown, M. C., Lunn, E. R., Tree, P. & Gordon, S. Evidence that very slow Wallerian degeneration in C57BL/ Ola mice is an intrinsic property of the peripheral nerve. Eur. J. Neurosci. 2, 802-808 (1990).
25. Deckwerth, T. L. & Johnson, E. M. Jr. Neurites can remain viable after destruction of the neuronal soma by programmed cell death (apoptosis). Dev. Biol. 165, 63-72 (1994).
26. Glass, J. D., Brushart, T. M., George, E. B. & Griffin, J. W. Prolonged survival of transected nerve fibres in C57BL/Ola mice is an intrinsic characteristic of the axon. J. Neurocytol. 22, 311-321 (1993).
27. S mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J. Neurosci. 23, 2833-2839 (2003).
28. S mice are resistant to paclitaxel (taxol) neuropathy. Ann. Neurol. 52, 442-447 (2002).
29. S mutant mice. J. Cereb. Blood Flow Metab. 24, 62-66 (2004).
30. S-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr. Biol. 14, 326-330 (2004).
31. S, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain 128, 405-416 (2005). The first paper to link axonal spheroid pathology in the CNS with Wallerian degeneration.
32. Saigoh, K. et al. Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nature Genet. 23, 47-51 (1999).
33. Comment in Nature Genet. 23, 10-11 (1999).
34. Beirowski, B. et al. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice. J. Neurosci. Meth. 134, 23-35 (2004).
35. Kerschensteiner, M., Schwab, M. E., Lichtman, J. W. & Misgeld, T. In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nature Med. 11, 572-577 (2005). The first real-time study of Wallerian degeneration in the CNS, and demonstration that AAD is a rapid degeneration process that is mechanistically linked to Wallerian degeneration.
36. Cheng, C. L. & Povlishock, J. T. The effect of traumatic brain injury on the visual system: a morphologic characterization of reactive axonal change. J. Neurotrauma 5, 47-60 (1988).
37. Tsai, J., Grutzendler, J., Duff, K. & Gan, W. B. Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches. Nature Neurosci. 7, 1181-1183 (2004).
38. Galvin, J. E., Uryu, K., Lee, V. M. & Trojanowski, J. Q. Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains α-, β-, and γ-synuclein. Proc. Natl Acad. Sci. USA 96, 13450-13455 (1999).
39. Liberski, P. P. & Budka, H. Neuroaxonal pathology in Creutzfeldt-Jakob disease. Acta Neuropathol. (Berl.) 97, 329-334 (1999).
40. Adle-Biassette, H. et al. Neuronal apoptosis does not correlate with dementia in HIV infection but is related to microglial activation and axonal damage. Neuropathol. Appl. Neurobiol. 25, 123-133 (1999).
41. Ferguson, B., Matyszak, M. K., Esiri, M. M. & Perry, V. H. Axonal damage in acute multiple sclerosis lesions. Brain 120, 393-399 (1997).
42. Trapp, B. D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
43. G93A fALS mouse. Neurobiol. Dis. 19, 293-300 (2005).
44. S does not attenuate mutant SOD1-mediated motor neuron disease. Neuromolecular Med. 5, 193-204 (2004).
45. Edgar, J. M. et al. Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J. Cell Biol. 166, 121-131 (2004).
46. Berliocchi, L. et al. Botulinum neurotoxin C initiates two different programs for neurite degeneration and neuronal apoptosis. J. Cell Biol. 168, 607-618 (2005).
47. + levels. Eur. J. Neurosci. 7, 1596-1602 (1995).
48. Ikegami, K. & Koike, T. Non-apoptotic neurite degeneration in apoptotic neuronal death: pivotal role of mitochondrial function in neurites. Neuroscience 122, 617-626 (2003). Demonstration that mitochondrial dysfunction is a key step in Wallerian degeneration in vitro.
49. S) is also protective against vincristine neuropathy. Neurobiol. Dis. 8, 155-161 (2001).
50. S) with improved preservation of neuromuscular synapses. Eur. J. Neurosci. 21, 271-277 (2005).
51. S) mouse. Proc. Natl Acad. Sci. USA 97, 11377-11382 (2000).
52. S) mouse. Proc. Natl Acad. Sci. USA 95, 9985-9990 (1998).
53. S chimeric protein and its constituent proteins in the central nervous system. Neuroscience (in the press).
54. Wang, J. et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J. Cell Biol. 179, 349-355 (2005).
55. Araki, T., Sasaki, Y. & Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010-1013 (2004).
56. Zhai, Q. et al. Involvement of the ubiquitin-proteasome system in the early stages of Wallerian degeneration. Neuron 39, 217-225 (2003).
57. Macinnis, B. L. & Campenot, R. B. Regulation of Wallerian degeneration and nerve growth factor withdrawal-induced pruning of axons of sympathetic neurons by the proteasome and the MEK/Erk pathway. Mol. Cell. Neurosci. 28, 430-439 (2005).
58. Ehlers, M. D. Deconstructing the axon: Wallerian degeneration and the ubiquitin-proteasome system. Trends Neurosci. 27, 3-6 (2004).
59. Coleman, M. P. & Ribchester, R. R. Programmed axon death, synaptic dysfunction and the ubiquitin proteasome system. Curr. Drug Targets CNS Neurol. Disord. 3, 227-238 (2004).
60. Wishart, T. M. et al. Transcriptional regulation of pituitary tumour transforming gene-1 by the neuroprotective WldS gene in mouse cerebellar granule cells and HEK293 cell lines. J. Physiol. 565P, C74 (2004).
61. Yamagishi, S. et al. Wallerian degeneration involves RHO/ RHO-kinase signaling. J. Biol. Chem. 280, 20384-20388 (2005).
62. Ikegami, K., Kato, S. & Koike, T. N-α-p-tosyl-L-lysine chloromethyl ketone (TLCK) suppresses neuritic degeneration caused by different experimental paradigms including in vitro Wallerian degeneration. Brain Res. 1030, 81-93 (2004).
63. Guertin, A. D., Zhang, D. P., Mak, K. S., Alberta, J. A. & Kim, H. A. Microanatomy of axon/glial signaling during Wallerian degeneration. J. Neurosci. 25, 3478-3487 (2005).
64. Martin, N. et al. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nature Genet. 32, 443-447 (2002).
65. Martini, R. The effect of myelinating Schwann cells on axons. Muscle Nerve 24, 456-466 (2001).
66. Ichihara, N. et al. Axonal degeneration promotes abnormal accumulation of amyloid β-protein in ascending gracile tract of gracile axonal dystrophy (GAD) mouse. Brain Res. 695, 173-178 (1995).
67. Singer, M., Flinker, D. & Sidman, R. L. Nerve destruction by colchicine resulting in suppression of limb regeneration in adult triturus. J. Exp. Zool. 131, 267-300 (1956).
68. Julien, J. P. Neurofilament functions in health and disease. Curr. Opin. Neurobiol. 9, 554-560 (1999).
69. Hirokawa, N. & Takemura, R. Molecular motors and mechanisms of directional transport in neurons. Nature Rev. Neurosci. 6, 201-214 (2005).
70. Zhao, C. et al. Charcot-Marie-Tooth disease type 2A caused by mutation in a microtubule motor KIF1Bβ. Cell 105, 587-597 (2001).
71. Reid, E. et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10). Am. J. Hum. Genet. 71, 1189-1194 (2002).
72. Hafezparast, M. et al. Mutations in dynein link motor neuron degeneration to defects in retrograde transport. Science 300, 808-812 (2003).
73. Raff, M. C., Whitmore, A. V. & Finn, J. T. Axonal self-destruction and neurodegeneration. Science 296, 868-871 (2002).
74. Burne, J. F., Staple, J. K. & Raff, M. C. Glial cells are increased proportionally in transgenic optic nerves with increased numbers of axons. J. Neurosci. 16, 2064-2073 (1996).
75. Sagot, Y. et al. Bcl-2 overexpression prevents motoneuron cell body loss but not axonal degeneration in a mouse model of a neurodegenerative disease. J. Neurosci. 15, 7727-7733 (1995).
76. Whitmore, A. V., Lindsten, T., Raff, M. C. & Thompson, C. B. The proapoptotic proteins Bax and Bak are not involved in Wallerian degeneration. Cell Death Differ. 10, 260-261 (2003).
77. Finn, J. T. et al. Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. J. Neurosci. 20, 1333-1341 (2000).
78. Gentleman, S. M., Nash, M. J., Sweeting, C. J., Graham, D. I. & Roberts, G. W. β-amyloid precursor protein (β APP) as a marker for axonal injury after head injury. Neurosci. Lett. 160, 139-144 (1993).
79. Stone, J. R. et al. Impaired axonal transport and altered axolemmal permeability occur in distinct populations of damaged axons following traumatic brain injury. Exp. Neurol. 190, 59-69 (2004).
80. Kornek, B. et al. Distribution of a calcium channel subunit in dystrophic axons in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain 124, 1114-1124 (2001).
81. S mice. J. Neurol. Sci. 233, 133-138 (2005).
82. Sasaki, S., Warita, H., Abe, K. & Iwata, M. Impairment of axonal transport in the axon hillock and the initial segment of anterior horn neurons in transgenic mice with a G93A mutant SOD1 gene. Acta Neuropathol. (Berl.) 110, 48-56 (2005).
83. Griffiths, I. et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280, 1610-1613 (1998).
84. Abrahams, P. H., Day, A. & Allt, G. The node of Ranvier in early Wallerian degeneration: a freeze-fracture study. Acta Neuropathol. (Berl.) 54, 95-100 (1981).
85. Ballin, R. H. & Thomas, P. K. Changes at the nodes of Ranvier during Wallerian degeneration: an electron microscope study. Acta Neuropathol. (Berl.) 14, 237-249 (1969).
86. Webster, H. D. Transient, focal accumulation of axonal mitochondria during the early stages of Wallerian degeneration. J. Cell Biol. 12, 361-383 (1962).
87. Lappe-Siefke, C. et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nature Genet. 33, 366-374 (2003).
88. Rasband, M. N. et al. CNP is required for maintenance of axon-glia interactions at nodes of Ranvier in the CNS. Glia 50, 86-90 (2005).
89. Craner, M. J., Hains, B. C., Lo, A. C., Black, J. A. & Waxman, S. G. Co-localization of sodium channel Nav1.6 and the sodium-calcium exchanger at sites of axonal injury in the spinal cord in EAE. Brain 127, 294-303 (2004).
90. 2+ exchanger. Proc. Natl Acad. Sci. USA 101, 8168-8173 (2004).
91. Brendza, R. P. et al. Use of YFP to study amyloid-β associated neurite alterations in live brain slices. Neurobiol. Aging 24, 1071-1077 (2003).
92. Brendza, R. P. et al. Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J. Clin. Invest. 115, 428-433 (2005).
93. Lunn, E. R., Brown, M. C. & Perry, V. H. The pattern of axonal degeneration in the peripheral nervous system varies with different types of lesion. Neuroscience 35, 157-165 (1990).
94. Donat, J. R. & Wisniewski, H. M. The spatio-temporal pattern of Wallerian degeneration in mammalian peripheral nerves. Brain Res. 53, 41-53 (1973).
95. Schlaepfer, W. W. Structural alterations of peripheral nerve induced by the calcium ionophore A23187. Brain Res. 136, 1-9 (1977).
96. Schlaepfer, W. W. Calcium-induced degeneration of axoplasm in isolated segments of rat peripheral nerve. Brain Res. 69, 203-215 (1974).
97. LoPachin, R. M. & Lehning, E. J. Mechanism of calcium entry during axon injury and degeneration. Toxicol. Appl. Pharmacol. 143, 233-244 (1997).
98. Iwata, A. et al. Traumatic axonal injury induces proteolytic cleavage of the voltage-gated sodium channels modulated by tetrodotoxin and protease inhibitors. J. Neurosci. 24, 4605-4613 (2004).
99. Bechtold, D. A. et al. Axonal protection in experimental autoimmune neuritis by the sodium channel blocking agent flecainide. Brain 128, 18-28 (2005).
100. Bechtold, D. A., Kapoor, R. & Smith, K. J. Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann. Neurol. 55, 607-616 (2004).
101. Lo, A. C., Black, J. A. & Waxman, S. G. Neuroprotection of axons with phenytoin in experimental allergic encephalomyelitis. Neuroreport 13, 1909-1912 (2002).
102. Hains, B. C., Saab, C. Y., Lo, A. C. & Waxman, S. G. Sodium channel blockade with phenytoin protects spinal cord axons, enhances axonal conduction, and improves functional motor recovery after contusion SCI. Exp. Neurol. 188, 365-377 (2004).
103. Fern, R., Ransom, B. R., Stys, P. K. & Waxman, S. G. Pharmacological protection of CNS white matter during anoxia: actions of phenytoin, carbamazepine and diazepam. J. Pharmacol. Exp. Ther. 266, 1549-1555 (1993).
104. Stys, P. K. Anoxic and ischemic injury of myelinated axons in CNS white matter: from mechanistic concepts to therapeutics. J. Cereb. Blood Flow Metab. 18, 2-25 (1998).
105. Waxman, S. G. Sodium channel blockers and axonal protection in neuroinflammatory disease. Brain 128, 5-6 (2005).
106. Kapoor, R., Davies, M., Blaker, P. A., Hall, S. M. & Smith, K. J. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann. Neurol. 53, 174-180 (2003).
107. Stys, P. K. Axonal degeneration in multiple sclerosis: is it time for neuroprotective strategies? Ann. Neurol. 55, 601-603 (2004).
108. Wang, M. S. et al. Calpain inhibition protects against Taxol-induced sensory neuropathy. Brain 127, 671-679 (2004).
109. 2+ channel activation of ryanodine receptors. Neuron 40, 53-63 (2003).
110. Mata, M., Staple, J. & Fink, D. J. Changes in intra-axonal calcium distribution following nerve crush. J. Neurobiol. 17, 449-467 (1986).
111. Brand-Schieber, E. & Werner, P. Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Exp. Neurol. 189, 5-9 (2004).
112. Bianchi, R. et al. Erythropoietin both protects from and reverses experimental diabetic neuropathy. Proc. Natl Acad. Sci. USA 101, 823-828 (2004).
113. Keswani, S. C., Leitz, G. J. & Hoke, A. Erythropoietin is neuroprotective in models of HIV sensory neuropathy. Neurosci. Lett. 371, 102-105 (2004).
114. Keswani, S. C. et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann. Neurol. 56, 815-826 (2004).
115. Siren, A. L. et al. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl Acad. Sci. USA 98, 4044-4049 (2001).
116. Sievers, C., Platt, N., Perry, V. H., Coleman, M. P. & Conforti, L. Neurites undergoing Wallerian degeneration show an apoptotic-like process with annexin V positive staining and loss of mitochondrial membrane potential. Neurosci. Res. 46, 161-169 (2003).
117. Nolte, C. et al. GFAP promoter-controlled EGFP-expressing transgenic mice: a tool to visualize astrocytes and astrogliosis in living brain tissue. Glia 33, 72-86 (2001).
118. 2+ indicator proteins in transgenic mice under TET control. PLoS Biol 2, e163 (2004).
119. Ghosh, N., DeLuca, G. C. & Esiri, M. M. Evidence of axonal damage in human acute demyelinating diseases. J. Neurol. Sci. 222, 29-34 (2004).
120. Raja, F., Sherriff, F. E., Morris, C. S., Bridges, L. R. & Esiri, M. M. Cerebral white matter damage in HIV infection demonstrated using β-amyloid precursor protein immunoreactivity. Acta Neuropathol. (Berl.) 93, 184-189 (1997).
121. Schwab, C., Steele, J. C. & McGeer, P. L. Dystrophic neurites are associated with early stage extracellular neurofibrillary tangles in the parkinsonism-dementia complex of Guam. Acta Neuropathol. (Berl.) 94, 486-492 (1997).
122. Dewar, D., Yam, P. & McCulloch, J. Drug development for stroke: importance of protecting cerebral white matter. Eur. J. Pharmacol. 375, 41-50 (1999).
123. Hughes, P. M. et al. Focal lesions in the rat central nervous system induced by endothelin-1. J. Neuropathol. Exp. Neurol. 62, 1276-1286 (2003).